Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alexander Kim

Pain Medicine Boston, MA Medical Doctor

NPI 1194082727 CMS profile 2175343

75 Francis St, Boston, MA 02115

Open in the dashboard

General payments

$3,928

75 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Kim of Boston, MA is reported in the CMS Open Payments database as having received $3,928 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,325 27
2024 General $705 10
2023 General $554 11
2022 General $293 4
2021 General $437 8
2020 General $614 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Kim
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Alexander Kim were reported at $1,325. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Alexander Kim Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $614 $284 $80–$910 $114
2021 $437 $399 $112–$1,219 $132
2022 $293 $455 $137–$1,484 $149
2023 $554 $484 $128–$1,495 $160
2024 $705 $498 $131–$1,540 $164
2025 $1,325 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Saluda Medical Americas, Inc. $1,407 24 payments
  2. Medtronic, Inc. $730 15 payments
  3. Boston Scientific Corporation $671 14 payments
  4. SPR Therapeutics, Inc $534 6 payments
  5. Abbott Laboratories $134 3 payments
  6. MML US, Inc. $133 2 payments
  7. Globus Medical, Inc. $128 1 payment
  8. Medtronic USA, Inc. $79 5 payments
  9. Nevro Corp. $42 2 payments
  10. DePuy Synthes Sales Inc. $37 2 payments
  11. Other $33 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,923 74 payments
  2. Travel and Lodging $5 1 payment
Products named General payments · program years 2020–2025
  1. Evoke $1,407 24 payments
  2. SPRINT PNS System $534 6 payments
  3. INTELLIS ADAPTIVESTIM $288 7 payments
  4. GENERAL - PAIN MANAGEMENT $252 5 payments
  5. INTELLIS $244 2 payments
  6. WaveWriter Alpha Prime 16 $190 2 payments
  7. Proclaim IPG $134 3 payments
  8. ReActiv8 $133 2 payments
  9. Senza $128 1 payment
  10. General - Therapies $86 1 payment
  11. Other $545 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

521

Median for Anesthesiology: 322

Drug cost

$12,615

Median for Anesthesiology: $8,738

Branded share of claims

2.7%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 85 $4,319
Buprenorphine Generic 16 $4,062
Gabapentin Generic 118 $1,386
Pregabalin Generic 88 $1,119
Tizanidine Hcl Generic 54 $483
Cyclobenzaprine Hcl Generic 41 $390
Methylprednisolone Generic 37 $291
Methocarbamol Generic 20 $187
Tramadol Hcl Generic 21 $154
Oxycodone Hcl Generic 27 $130

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$171,651

Of which drugs: $10,100

Medicare patients

373

Average age 74

Services billed

23,228

233 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 28%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 25%
COPD 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 165 19,921 $2,040
Injection, methylprednisolone acetate, 80 mg J1040 Office 29 29 $223
Injection, methylprednisolone acetate, 40 mg J1030 Office 24 43 $216
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 37 737 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record